Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/6/e004799.full |
| _version_ | 1811329410902523904 |
|---|---|
| author | Jeong Hun Kim Won Suk Lee Seung Joon Lee Hannah Yang Hong Jae Chon Chan Kim Jin Hyoung Kim Byung cheol Ahn Dong Sung Kim Yoonki Heo Eun-Jin Go Jung Sun Yum |
| author_facet | Jeong Hun Kim Won Suk Lee Seung Joon Lee Hannah Yang Hong Jae Chon Chan Kim Jin Hyoung Kim Byung cheol Ahn Dong Sung Kim Yoonki Heo Eun-Jin Go Jung Sun Yum |
| author_sort | Jeong Hun Kim |
| collection | DOAJ |
| first_indexed | 2024-04-13T15:44:41Z |
| format | Article |
| id | doaj.art-bbc3b1d7c9054e4a9ae0ea54ffe2e9ef |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-04-13T15:44:41Z |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-bbc3b1d7c9054e4a9ae0ea54ffe2e9ef2022-12-22T02:41:03ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-06-0110610.1136/jitc-2022-004799Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockadeJeong Hun Kim0Won Suk Lee1Seung Joon Lee2Hannah Yang3Hong Jae Chon4Chan Kim5Jin Hyoung Kim6Byung cheol Ahn7Dong Sung Kim8Yoonki Heo9Eun-Jin Go10Jung Sun Yum11Department of Biomedical Science, CHA University, Seongnam, Gyeonggi-do, Korea (the Republic of)Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)Department of Biomedical Science, CHA University, Seongnam, Gyeonggi-do, Korea (the Republic of)Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Korea (the Republic of)instructorYouth Bio Global, Ltd, Seoul, Republic of Korea4CHA Vaccine Institute, Seoul, Korea, Republic ofLaboratory of Translational Immuno-Oncology, Seongnam, Gyeonggi-do, Korea (the Republic of)CHA Vaccine Institute, Seongnam, Gyeonggi-do, Korea (the Republic of)Laboratory of Translational Immuno-Oncology, Seongnam, Gyeonggi-do, Korea (the Republic of)CHA Vaccine Institute, Seongnam, Gyeonggi-do, Korea (the Republic of)https://jitc.bmj.com/content/10/6/e004799.full |
| spellingShingle | Jeong Hun Kim Won Suk Lee Seung Joon Lee Hannah Yang Hong Jae Chon Chan Kim Jin Hyoung Kim Byung cheol Ahn Dong Sung Kim Yoonki Heo Eun-Jin Go Jung Sun Yum Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade Journal for ImmunoTherapy of Cancer |
| title | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
| title_full | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
| title_fullStr | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
| title_full_unstemmed | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
| title_short | Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade |
| title_sort | intratumoral immunotherapy using a tlr2 3 agonist l pampo induces robust antitumor immune responses and enhances immune checkpoint blockade |
| url | https://jitc.bmj.com/content/10/6/e004799.full |
| work_keys_str_mv | AT jeonghunkim intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT wonsuklee intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT seungjoonlee intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT hannahyang intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT hongjaechon intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT chankim intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT jinhyoungkim intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT byungcheolahn intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT dongsungkim intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT yoonkiheo intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT eunjingo intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade AT jungsunyum intratumoralimmunotherapyusingatlr23agonistlpampoinducesrobustantitumorimmuneresponsesandenhancesimmunecheckpointblockade |